TY - JOUR T1 - Gender disparities in international COVID-19 clinical trial leadership JF - medRxiv DO - 10.1101/2020.08.02.20166751 SP - 2020.08.02.20166751 AU - Muge Cevik AU - Syed Arefinul Haque AU - Jennifer Manne-Goehler AU - Krutika Kuppalli AU - Paul E. Sax AU - Maimuna S. Majumder AU - Chloe Orkin Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/04/2020.08.02.20166751.abstract N2 - The COVID-19 pandemic offers considerable possibilities for research and leadership that might equalize opportunity in a new field; however, our study finds instead that more than two-thirds of investigators leading COVID-19-related clinical studies are predicted to be men. These gender disparities in trial leadership during the pandemic suggest that the structural reproduction of inequalities in research has taken place once again in this new academic field. This indicates that policies are needed to facilitate the identification and implementation of strategies to correct gender bias. The active participation of women, trans and gender-nonconforming individuals are needed in research to drive scientific discovery and innovation as well as to better address health disparities.Competing Interest StatementMC, SH, JS, KK, MM have none to disclose. CO has received honoraria, fees for lectures, and advisory boards from Gilead, MSD, Viiv, and Janssen. She has also received research grants to her institution from the above-mentioned companies. PES has received honoraria, fees for lectures, and advisory boards from Gilead, Merck, Janssen, and ViiV; he has also received research grants to his institution from Gilead and ViiV.Funding StatementNo funding receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe repository of the datasets used to collect and analyse the data available at https://osf.io/k2r57/. ER -